Kate – Interview 13
Kate and her husband took part in a trial comparing injections of grass pollen antigen against a placebo as a way to reduce hay fever. Kate was in the experimental group and her husband in the placebo group.
Kate and her husband have bad hay fever. They saw an advert in a local paper seeking volunteers for a trial of immunotherapy for grass pollen allergy, and went along to see if they were eligible. Allergy tests showed they were both allergic to grass pollen, so they agreed to join the trial.
The trial involved regular fortnightly injections of either grass pollen antigen or a placebo for a few months each spring to summer for three years, as well as maintaining a diary of their symptoms and medication needed over the rest of the summer. It was explained to them that there was a small risk of going into anaphylactic shock after the injection, so they had to stay at the hospital for a while with a doctor nearby each time. It took a lot of time commitment and travelling to take part. Travel expenses were paid, and they were given free hay fever tablets, eye drops and nasal sprays as part of the trial. Kate was hoping they would benefit personally from the trial in terms of their own hay fever, but they also felt it was important to help others with hay fever by finding out is this treatment worked.
The trial was meant to be double blind – neither the trial staff nor the participants were meant to know whether they were getting the injection of antigen or the placebo. However, from her allergic reactions at the site of the injection it was quickly obvious to Kate that she was getting the antigen, while her husband had no reaction and they assumed he was getting the placebo. At the end of the trial, they were told they had guessed correctly, and her husband was offered a course of the antigen injections, which the trial had found did lead to a reduction in hay fever symptoms. Kate is disappointed that the injection has not since been made widely available on the NHS, but she understands it is quite an expensive thing to offer everyone and many people would find it too much of a commitment.
They were impressed by the research nurse who ran the trial, and liked the fact that it was him they saw every time. His willingness to share information with them and the relationship they built up helped motivate them to stay in the trial over the whole three years.
Kate has also recently taken part in an experimental study of a new type of surgery for a lump in her hip, femoro-acetabular surgery. This was not a randomised trial, but surgeons can only provide it if they take part in an audit run by the National Institute for Health and Clinical Excellence of how safe and effective the procedure is. For Kate, it was either a choice of taking part in this study or not having surgery. She likes exercise and wanted to improve her hip function so she took part and has been followed up. She is very happy with the results, but explains that in studies where patients and doctors choose a treatment rather than the treatment being decided by random allocation, there may be a bias in the type of people having the procedure. This means we cannot necessarily assume everyone in the population would get the same level of benefit.